(Reuters) – Vaccines for COVID-19 being developed and manufactured for the 2024-2025 campaign should target one of the currently dominant JN.1 variants and JN.1-derived subvariants such as KP.2, the U.S. Food and Drug Administration’s staff reviewers said on Monday.
(Reporting by Christy Santhosh and Leroy Leo in Bengaluru; Editing by Shilpi Majumdar)
